Northern Trust’s Oramed Pharmaceuticals ORMP Stock Holding History

Northern Trust’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$889K	Buy	+184,920	New	+$736K	﹤0.01%	3506
2023 Q3	–	Sell	-11,569	Closed	-$41.4K	–	4509
2023 Q2	$41.4K	Hold	11,569	–	–	﹤0.01%	4260
2023 Q1	$25.2K	Sell	11,569 -263	-2%	-$835	﹤0.01%	4406
2022 Q4	$142K	Sell	11,832 -2,093	-15%	-$16.3K	﹤0.01%	3991
2022 Q3	$90K	Buy	13,925 +285	+2%	+$2.31K	﹤0.01%	4144
2022 Q2	$62K	Sell	13,640 -268,738	-95%	-$1.44M	﹤0.01%	4342
2022 Q1	$2.44M	Buy	282,378 +39,253	+16%	+$402K	﹤0.01%	3000
2021 Q4	$3.47M	Buy	243,125 +17,294	+8%	+$362K	﹤0.01%	2924
2021 Q3	$4.96M	Buy	225,831 +14,749	+7%	+$251K	﹤0.01%	2734
2021 Q2	$2.82M	Buy	+211,082	New	+$2.41M	﹤0.01%	3187
2019 Q1	–	Sell	-18,269	Closed	-$55K	–	4254
2018 Q4	$55K	Buy	18,269 +259	+1%	+$1.07K	﹤0.01%	4034
2018 Q3	$88K	Buy	+18,010	New	+$93.5K	﹤0.01%	4051

Other funds holding ORMP

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust's ORMP Position: Q2 2026 in Review

Northern Trust opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 184,920 shares worth $889K. The stake represents ﹤0.01% of the portfolio and ranks #3506 among its holdings. This is a return to the name: Northern Trust previously reported a position in ORMP as recently as Q2 2023.

Northern Trust first reported a position in ORMP in Q3 2018 and has held it in 12 quarters since. The position peaked at $4.96M in Q3 2021. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

Northern Trust held 184,920 shares of Oramed Pharmaceuticals worth $889K as of Q2 2026.
Oramed Pharmaceuticals was a new Northern Trust position in Q2 2026.
Oramed Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3506 holding.
Northern Trust first reported a position in Oramed Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
Northern Trust's Oramed Pharmaceuticals position peaked at $4.96M in Q3 2021.
84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.